July 9, 2013: by longevinex.com
Las Vegas, NV (July 9, 2013) – In an effort to help ensure its product is not removed from the marketplace by onerous requirements stipulated by regulatory agencies or by covert efforts to undermine its product quality, Longevinex® announces today its proprietary red wine anti-aging capsules have passed stringent sub-acute toxicity testing, a requirement for further human testing.
Longevinex® red wine capsules did not produce significant toxic side effects or mortality in laboratory mice at human equivalent doses of 3500 and 7000 milligrams per day (~10-20 oral capsules/day) in testing conducted under the supervision of Hannah R. Vasanthi PhD, at the Department of Biotechnology, Pondicherry University, India. A complete report was published in the journal of Food & Chemical Toxicology.
As a dietary supplement, Longevinex® is currently the only commercially available red wine capsule to successfully undergo toxicity testing as outlined by New Dietary Ingredient guidelines described by the Food & Drug Administration (FDA).
While toxicity testing is expensive, Longevinex® will not increase its retail price to consumers. “It is just a level of assurance that consumers desire and the FDA continues to demand,” says Bill Sardi, managing partner for Longevinex®.
Sardi says the FDA and the pharmaceutical industry are both overtly and covertly pushing for resveratrol to become a drug. If declared a drug, sub-acute toxicity testing would be required to keep the product available to consumers, he says.
A few thousand Americans depend upon Longevinex® to maintain healthy eyes, heart, brain and blood circulation and “we don’t want any actions by regulatory agencies to restrict availability of Longevinex® to needy consumers,” says Sardi.
There were no adverse changes in brain, heart, liver, kidney, spleen and sex organs noted after 28-days of dietary supplementation in laboratory animals. Nor were there any abnormal levels of liver enzymes, kidney toxicity or irregular blood studies such as blood sugar, cholesterol, or triglycerides.
Tissue slides obtained from heart, brain, liver and kidneys showed Longevinex® produced obviously healthier tissues than observed among animals given plain resveratrol or control animals given no active treatment (see images below).
Tissue images of heart and brain
Tissue images of kidney and liver
In accordance with established testing methods, laboratory mice were subjected to sub-acute doses of Longevinex® dietary supplement (sub-acute dosing is defined as toxicity that emanates as a result of repeated daily dosing of chemicals to experimental animals versus acute toxicity which tests for adverse effect occurring within a short time following administration such as a single dose.) Such testing is required for controlled human trials.
Longevinex® alleges Big Pharma is making covert efforts to classify synthetic resveratrol as a drug and to illigitimize botanically-derived resveratrol from herbal sources. Longevinex® is produced from Giant Knotweed, the most concentrated and abundant natural source of resveratrol.
Resveratrol researchers worldwide continue to echo the false idea that resveratrol is not biologically available (that is, makes it past the liver which detoxifies incoming molecules) when it has been clearly demonstrated that liver metabolites of resveratrol are equally effective biologically. One objective is to create bogus science to dismiss natural resveratrol and substitute patentable resveratrol-like drugs (called analogs).
Longevinex® also faces more pointed opposition. Longevinex® has received an unsigned letter on a major university letterhead from unidentified red wine molecule researchers which threatens that Longevinex® will be put out of business if it continues in its attempts to scientifically validate its product.
“It is important for Longevinex®, as the leading and best-tested brand, to validate the safety and effectiveness of its product beyond what is required for common dietary supplements and that no spurious efforts to undermine the product will be successful,” Sardi emphasizes.
Longevinex® has generated unequalled science, some never having been demonstrated in biology before.
For example, in an earlier published study, unlike plain red wine resveratrol, Longevinex® was demonstrated in two species of animals, in both long and short-term tests, to exhibit no cytotoxicity (cell killing effect) at all doses tested (100 to 7000 milligrams).
Normally resveratrol is an antioxidant at low dose but undesirably promotes oxidation when given in mega doses. In animal studies, excessive-dose (more than 350 mg) resveratrol increases the area of scarring in experimentally induced heart attacks. Remarkably, Longevinex® does not. It is the first time in biology this has been demonstrated.
Longevinex® was shown to protect the animal heart from damage induced by an experimentally-induced heart attack about twice as well as a plain red wine pill. Evidence for this was confirmed by independent microRNA testing conducted by researchers at the National Institutes of Health.
In a study published in 2008 Longevinex® mimicked the genetic activity of a calorie-restricted diet, which is known to double the lifespan and healthspan of laboratory animals.
Life-long adherence to a limited calorie diet in laboratory mice activates 831 longevity genes. Short-term calorie restriction activates 198 longevity genes. Red wine resveratrol, the molecule believed to be responsible for the French Paradox (the fact the red wine-drinking French consume more fat and have higher levels of cholesterol but much lowers rates of death from heart attacks) activates about the same number of genes (225) as a limited calorie diet over the short-term.
Researchers believe it would take a lifetime for resveratrol supplementation to equal the genomic effect of calorie restriction. However, Longevinex® activated 82% (677) of those 831 longevity genes in just 12 weeks and double the number of genes overall (1711).
Sardi claims “the science shows consumers might have to take red wine resveratrol pills for 50 years (18,250 pills) at a cost of around $10,000 to activate the same number of longevity genes that less than 100 Longevinex® capsules would activate for less than $100.
“If this animal science applies to humans, consumers taking plain resveratrol pills are wasting their money,” says Sardi. ®2013 Resveratrol Partners LLC
Food Chem Toxicol. 2013 Jun 29. pii: S0278-6915(13)00416-X. doi: 10.1016/j.fct.2013.06.037. [Epub ahead of print]
Department of Biotechnology, School of Life Sciences, Pondicherry University, Puducherry – 605104, India. Electronic address: firstname.lastname@example.org.
Longevinex, a nutraceutical formulation containing Resveratrol as the main component along with other polyphenolics exhibits diverse health benefits but systemic safety studies are lacking. Hence, to test the safety of Longevinex use for therapeutic purposes, 50 Sprague Dawley rats were randomly divided into 5 groups (n=10; 5Male, 5Female) wherein group I as vehicle treated control, group II and group III received 50 mg and 100 mg/kilogram (2.2 lbs) of plain Resveratrol respectively and group IV and group V received 50 mg and 100 mg/kilogram of Longevinex respectively for a period of 28days. All toxicological parameters were analysed as per OECD-407 guidelines. Results showed treatment with Resveratrol and Longevinex did not result in any mortality of rats neither did they exhibit any clinical signs of toxicity. Hematological and biochemical analysis of serum enzymes and metabolites were not significantly altered between Longevinex and control rats. Likewise, histopathological analysis for various organs did not reveal significant changes in the vital organs of the treated rats. The study revealed that there were no significant treatment related adverse effects in rats exposed to Longevinex for 28 days and considered safe at the given dose where compared to plain Resveratrol.